Statins are diabetogenic - Myth or reality?

Atherosclerosis Supplements

Volumn 13, Issue 1, 2012, Pages 1-10

  Sattar, Naveed ^a   Taskinen, Marja Riitta ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Diabetogenic; Evidence; New onset diabetes; Risk; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; GLUCOSE; INSULIN; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETOGENESIS; DRUG EFFECT; DRUG EFFICACY; DRUG LABELING; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS AS TOPIC; RISK;

EID: 84865562586     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.06.001     Document Type: Article

References (69)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
2. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
3. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
4. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
5. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
6. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
7. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993, 11:309-317.
8. Stamler J. Established major coronary risk factors. Coronary heart disease: from aetiology to public health 1992, Oxford University Press, Oxford. M. Marmot, P. Elliott (Eds.).
9. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434-444.
10. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
11. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the west of Scotland coronary prevention study. Circulation 2001, 103:357-362.
12. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
13. Gannage-Yared M.H., Azar R.R., Amm-Azar M., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005, 54:947-951.
14. Costa A., Casamitjana R., Casals E., et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 2003, 20:743-745.
15. Szendroedi J., Anderwald C., Krssak M., et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009, 32:209-214.
16. Rajpathak S.N., Kumbhani D.J., Crandall J., Barzilai N., Alderman M., Ridker P.M. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
17. Mills E.J., Wu P., Chong G., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011, 104:109-124.
18. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 2011, 305:2556-2564.
19. Waters D.D., Ho J.E., DeMicco D.A., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011, 57:1535-1545.
20. Culver A.L., Ockene I.S., Balasubramanian R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med 2012, 172:144-152.
21. Preiss D., Sattar N. Pharmacotherapy: statins and new-onset diabetes-the important questions. Nat Rev Cardiol 2012.
22. Gu K., Cowie C.C., Harris M.I. Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc 1999, 281:1291-1297.
23. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979, 241:2035-2038.
24. Manson J.E., Colditz G.A., Stampfer M.J., et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151:1141-1147.
25. UK prospective diabetes study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997, 20:1683-1687.
26. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
27. ADA VI. Prevention, management of complications. Diabetes Care 2011, 34:S30. Table 11.
28. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
29. Sampson U.K., Linton M.F., Fazio S. Are statins diabetogenic?. Curr Opin Cardiol 2011, 26:342-347.
30. Kruit J.K., Brunham L.R., Verchere C.B., Hayden M.R. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010, 21:178-185.
31. Yada T., Nakata M., Shiraishi T., Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999, 126:1205-1213.
32. Mabuchi H., Higashikata T., Kawashiri M., et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005, 12:111-119.
33. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006, 49:1881-1892.
34. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001, 507:357-361.
35. Hao M., Head W.S., Gunawardana S.C., Hasty A.H., Piston D.W. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007, 56:2328-2338.
36. Kruit J.K., Kremer P.H., Dai L., et al. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010, 53:1110-1119.
37. Nakata M., Uto N., Maruyama I., Yada T. Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6. Cell Struct Funct 1999, 24:451-455.
38. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Ehses J.A. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009, 24:325-331.
39. Ehses J.A., Lacraz G., Giroix M.H., et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009, 106:13998-14003.
40. Ehses J.A., Perren A., Eppler E., et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007, 56:2356-2370.
41. Boni-Schnetzler M., Thorne J., Parnaud G., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008, 93:4065-4074.
42. Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526.
43. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
44. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273:24266-24271.
45. Abderrahmani A., Niederhauser G., Favre D., et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007, 50:1304-1314.
46. Cnop M., Hannaert J.C., Grupping A.Y., Pipeleers D.G. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002, 143:3449-3453.
47. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004-1010.
48. Roehrich M.E., Mooser V., Lenain V., et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003, 278:18368-18375.
49. Drew B.G., Rye K.A., Duffy S.J., Barter P., Kingwell B.A. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012, 8:237-245.
50. Stancakova A., Kuulasmaa T., Paananen J., et al. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes 2009, 58:2129-2136.
51. Moutzouri E., Liberopoulos E., Mikhailidis D.P., et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011, 65:1141-1148.
52. Sabatine M.S., Wiviott S.D., Morrow D.A., McCabe C.H., Cannon C.P. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy (abstract). Circulation 2004, 110(III):834.
53. Yamakawa T., Takano T., Tanaka S., Kadonosono K., Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008, 15:269-275.
54. Simsek S., Schalkwijk C.G., Wolffenbuttel B.H. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes-the CORALL study. Diabet Med 2011.
55. ® tablet) - LIVALO effectiveness and safety (LIVES) study. Jpn Pharmacol Ther 2008, 36:709-731.
56. Teramoto T., Yokote K., Urashima M., Shimano H., Saito Y., Group L.S.E. A large-scale survey on cardia-cerebrovascular events during pitavastatin (LiVALO tablet) therapy in Japanese patients with hypercholesterolemia - LiVALO effectiveness and safety study extension (LIVES study extension). Jpn Pharmacol Ther 2011, 39:789-803.
57. Yamazaki T., Kishimoto J., Ito C., et al. Japan prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int 2011, 2:134-140. Investigators, f. t. J.-P. s.
58. Sukhija R., Prayaga S., Marashdeh M., et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009, 57:495-499.
59. Kryzhanovski V., Gumprecht J., Zhu B., Yu C.Y., Hounslow N., Sponseller C.A. Atorvastatin but not pitavastatin significantly increases fasting plasma glucose in patients with type 2 diabetes and combined dyslipidemia. J Am Coll Cardiol 2011, 57:575.
60. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. J Am Med Assoc 2004, 292:1307-1316.
61. FDA FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs 2012.
62. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 1997, 20:614-620.
63. Knopp R.H., d'Emden M., Smilde J.G., Pocock S.J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006, 29:1478-1485.
64. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
65. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The care investigators. Circulation 1998, 98:2513-2519.
66. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
67. Sever P.S., Poulter N.R., Dahlof B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: anglo-Scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005, 28:1151-1157.
68. Ting R.Z., Yang X., Yu L.W., et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol 2010, 9:77.
69. Marder S.R., Essock S.M., Miller A.L., et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161:1334-1349.